DeCure for Agammaglobulinemia 8b, autosomal recessive
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for agammaglobulinemia 8b, autosomal recessive — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAgammaglobulinemia 8b, autosomal recessive maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for agammaglobulinemia 8b, autosomal recessive is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transcription factor 3 (TCF3) — TCF3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YPA · 2.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Agammaglobulinemia 8b, autosomal recessive, is a congenital antibody deficiency characterised by severe depletion of peripheral B-cells. The underlying mechanism is impairment in early B-cell development, caused by mutations in components of the pre-B-cell receptor complex or downstream signalling molecules. In a cohort of 87 Iranian patients with congenital agammaglobulinemia, molecular investigation was performed on 51 patients. Among these, 39 cases had BTK mutations (including one novel mutation), 5 cases had µ-heavy chain mutations (three novel), and 1 case had Igα deficiency. The autosomal recessive forms (µ-heavy chain and Igα) were therefore rare in this cohort, accounting for 6 of the 51 genotyped patients.
The same study reported that BTK-deficient and autosomal recessive agammaglobulinemia patients differ significantly regarding clinical and immunologic characteristics. However, no comprehensive correlation was found between the type of responsible BTK mutation and the severity of the clinical phenotype. The earlier literature, from 1960, describes idiopathic acquired agammaglobulinemia as a separate condition that can be associated with thymoma, but that form is not congenital and is not the autosomal recessive 8b type. The 1960 paper notes that congenital agammaglobulinemia was then understood as a recessive sex-linked gene affecting only males, which corresponds to X-linked agammaglobulinemia (BTK deficiency), not the autosomal recessive forms.
No treatment trials or drug interventions are reported in these abstracts. The natural history and genotype-phenotype correlations for autosomal recessive agammaglobulinemia 8b remain poorly defined because the condition is very rare. What is missing is a larger, multi-centre cohort that can systematically genotype patients with early B-cell defects, correlate specific mutations with clinical outcomes, and provide a basis for designing any future therapeutic trials. Without such data, no drug can be evaluated for this specific genetic form.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1960 · 104 citations
Idiopathic Acquired Agammaglobulinemia Associated with Thymoma
AbstractAGAMMAGLOBULINEMIA is an uncommon condition the underlying mechanism of which is fairly well understood in the majority of cases. Congenital agammaglobulinemia is the result of a recessive sex-linked gene, affecting males only, and becomes clinically manifest in early childhood. The acquired form affects previously healthy males and females and is usually secondary to lymphomas, injury to lymphoid tissue by x-rays or nitrogen mustards, multiple myeloma or other diseases characterized by dysproteinemia. In a small proportion of the cases no cause for the protein disturbance can be found, these being designated as cases of "idiopathic acquired agammaglobulinemia." Forty-four such cases have . . .
INDIGO (University of Illinois at Chicago) · 2016 · 0 citations · open access
Cohort of Iranian Patients with Congenital Agammaglobulinemia: Mutation Analysis and Novel Gene Defects
Abstract<b>Objectives:</b> Impairment in early B-cell development can cause a predominantly antibody deficiency with severe depletion of peripheral B-cells. Mutations in the gene encoding for Bruton’s-tyrosine-kinase (BTK) and the components of the pre-B-cell receptor complex or downstream signaling molecules have been related to this defect in patients with agammaglobulinemia. <b>Methods:</b> Iranian patients with congenital agammaglobulinemia were included and the correlation between disease-causing mutations and parameters such as clinical and immunologic phenotypes were evaluated in available patients. <b>Results:</b> Out of 87 patients, a molecular investigation was performed on 51 patients leading to identification of 39 cases with BTK (1 novel mutation), 5 cases of µ-heavy chain (3 novel mutations) and 1 case of Igα-deficiencies. <b>Conclusion:</b> Although there is no comprehensive correlation between type of responsible <i>BTK</i> mutation and severity of clinical phenotype, our data suggest that BTK-deficient and autosomal recessive agammaglobulinemia patients differ significantly regarding clinical/immunologic characteristics.
Cohort of Iranian Patients with Congenital Agammaglobulinemia: Mutation Analysis and Novel Gene Defects
Abstract<b>Objectives:</b> Impairment in early B-cell development can cause a predominantly antibody deficiency with severe depletion of peripheral B-cells. Mutations in the gene encoding for Bruton’s-tyrosine-kinase (BTK) and the components of the pre-B-cell receptor complex or downstream signaling molecules have been related to this defect in patients with agammaglobulinemia. <b>Methods:</b> Iranian patients with congenital agammaglobulinemia were included and the correlation between disease-causing mutations and parameters such as clinical and immunologic phenotypes were evaluated in available patients. <b>Results:</b> Out of 87 patients, a molecular investigation was performed on 51 patients leading to identification of 39 cases with BTK (1 novel mutation), 5 cases of µ-heavy chain (3 novel mutations) and 1 case of Igα-deficiencies. <b>Conclusion:</b> Although there is no comprehensive correlation between type of responsible <i>BTK</i> mutation and severity of clinical phenotype, our data suggest that BTK-deficient and autosomal recessive agammaglobulinemia patients differ significantly regarding clinical/immunologic characteristics.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
